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Summary In previous studies we have shown down-regulation of class I major histocompatibility complex
(MHC) expression in a significant proportion of primary cervical carcinomas, which was found to be strongly
correlated with loss of expression of the transporter associated with antigen presentation (TAP). By contrast,
class II MHC expression was frequently up-regulated on neoplastic keratinocytes in these malignancies. In
order to investigate whether these changes are associated with biological behaviour of the tumours, 20 cervical
carcinomas were analysed for MHC (HLA-A, HLA-B/C, HLA-DR) and TAP-1 expression in the primary
tumours and in lymph node metastases by immunohistochemistry. The results showed a significant increase in
the prevalence of HLA-A and HLA-B/C down-regulation in metastasised neoplastic cells as compared with
the primary tumour (P = 0.01). In all cases this was accompanied by loss of TAP-I expression. Up-regulated
HLA-DR expression was found exclusively in primary tumours and was absent in the corresponding
metastases (P= 0.002). These data are consistent with the hypothesis that loss of TAP-1 and the consequent
down-regulation of class I MHC expression provides a selective advantage for neoplastic cervical cells during
metastasis. Furthermore, the lack of class II MHC expression in metastasised cells either reflects a different
local lymphokine production or indicates that these cells may have escaped CD4+ cytotoxic T-lymphocyte
(CTL)-mediated killing.
Recognition of antigen by the cellular immune system is
dependent on the function of major histocompatibility com-
plex (MHC) cell-surface molecules, encoded by the HLA
genes in human. Class I MHC molecules preferably present
endogenous proteins to CD8+ cytotoxic T lymphocytes
(CTLs) as small antigenic peptides (Townsend et al., 1985).
These peptides are generated by degradation of proteins in
the cytosol, possibly involving the proteasome complex
(Goldberg & Rock, 1992). Subsequently peptides are
translocated into the endoplasmic reticulum (ER) by the
transporter associated with antigen presentation (TAP)
(Trowsdale et al., 1990; Spies et al., 1990; Neefjes et al., 1993;
Shepherd et al., 1993). The population of class I MHC
molecules with allelic variation in the vicinity of the antigen-
binding cleft allows a wide variety of peptide sequences to
bind to class I MHC in the ER (Falk et al., 1990), resulting
in their presentation at the cell surface. The MHC-antigenic
peptide complex can then activate specific CTLs to pro-
liferate, and these will eventually destroy the antigen-
presenting cell (Townsend et al., 1985).
Down-regulation of class I MHC expression has frequently
been reported in human malignancies (Ruiz-Cabello et al.,
1991). Such down-regulation would supply a selective growth
advantage for malignant tumours by allowing neoplastic cells
to escape CTL-mediated destruction. Indeed when class I
MHC expression is lost in breast (Concha et al., 1991) or
laryngeal (Esteban et al., 1989) carcinomas, a significantly
poorer clinical outcome is found.
Expansion of an antigen-specific CTL population in vivo
mostly depends on interleukin 2 (IL-2) production by
activated T-helper (Th) cells. This activation is mediated by
recognition of opsonised exogenous or endogenous antigen in
the context of class II MHC molecules, expressed on profes-
sional antigen-presenting cells (APCs). In addition, class II
MHC expression can be up-regulated on non-professional
APCs, as has been observed in a variety of human malignan-
cies (Sakai et al., 1987; van den Ingh et al., 1987; Paterson et
al., 1988). Such up-regulated class II MHC expression has
been reported to have a positive (Esteban et al., 1990) or
negative (Ruiter et al., 1986) effect with regard to prognosis.
Changes in both class I and II MHC expression have been
found in a substantial number of premalignant and malig-
nant lesions of the uterine cervix, containing human papil-
lomavirus (HPV) genotypes (Connor & Stern, 1990; Glew et
al., 1992, 1993; Cromme et al., 1993a). Down-regulation of
class I MHC expression in cervical carcinomas is apparently
post-transcriptionally controlled (Cromme et al., 1993b). This
is consistent with the observation that class I MHC loss is
frequently associated with a failure to detect one of the
subunits of the transporter associated with antigen presenta-
tion (TAP-1) (Cromme et al., 1993c).
However, little is known about the biological relevance of
the observed TAP-1 loss and the consequent down-regulation
of class I MHC expression in cervical malignancies. Also, the
influence of up-regulation of class II MHC is still poorly
understood. Evidence of progression is provided by the
presence of metastases in the draining lymph nodes.
Therefore we investigated in this study whether immmuno-
histochemically determined changes in MHC and TAP-1 ex-
pression are related to metastasis in HPV-positive cervical
carcinomas.
The results showed that loss of class I MHC expression
was significantly more frequent in metastases as compared
with the primary tumour, and was always associated with
loss of TAP-1 expression. Furthermore up-regulated HLA-
DR expression was shown to be restricted to the primary
tumour site, since no metastasised neoplastic cells were found
to express HLA-DR.
Materials and methods
Tissues
Tissues were obtained from patients with cervical carcinoma
stage IB or IIA who were treated at the Free University
Hospital in Amsterdam. These patients underwent radical
surgery combined with pelvic lymph node dissection. Twenty
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patients diagnosed as having neoplastic tumour cells in the
locoregional lymph nodes were entered into the study. From
all primary tumours and lymph node metastases represen-
tative paraffin tissue blocks were selected and serially cut to
4p1m sections. To ensure the presence of tumour, the first
and last slide from each series were stained routinely with
haematoxylin-eosin (H&E) and subjected to microscopic
examination. Slides of primary tumours and metastatic
lymph nodes were used for immunohistochemistry and
polymerase chain reaction (PCR) analysis.
HPV DNA detection
The presence of HPV genotypes was analysed by PCR
analysis on five tissue sections as described previously
(Cromme et al., 1993a), employing a general primer (GP5/6),
type-specific primer-mediated PCR strategy (Snijders et al.,
1990; van den Brule et al., 1990; Walboomers et al., 1992).
DNA from SiHa and HeLa cell lines, which contain HPV 16
and 18 DNA respectively, served as positive controls for the
HPV PCR. Quality of target DNA for PCR purposes was
analysed by PCR using human P-globin gene-specific primers.
Liver sections, cut between carcinoma samples, were analysed
by PCR to check for contamination during tissue processing
and were consistently negative for HPV, while the ,-globin
primer set gave a positive PCR result.
Immunohistochemistry
Immunohistochemical staining was performed as previously
described (Cromme et al., 1993a). Briefly, sections adhered to
coated [0.1% (w/v) poly-L-lysine) slides were deparaffinised
with xylene, rehydrated and endogenous peroxidase was
blocked by incubating for 30 min with methanol, containing
0.3% (v/v) hydrogen peroxide. After rinsing in phosphate-
buffered saline, pH 7.4 (PBS), sections of each biopsy were
processed according to the appropriate protocol for the
different primary antibodies (Table I).
After pretreatment and washing repeatedly in PBS, sec-
tions were preincubated with normal goat (1:20) or horse
(1:50) serum, depending on the secondary antibodies used,
for 15min and then incubated with primary antibodies
(Table I).
Bound murine antibodies were detected with a biotinylated
horse anti-mouse Ab, 1:500 (Vector Lab., Burlingame, CA,
USA), bound rabbit antibodies with a biotinylated goat anti-
rabbit Ab, 1:500 (Vector Lab.). Detection of binding of
secondary antibody was performed using horseradish perox-
idase coupled to avidin-biotin complex, 1:500 (Vector Elite,
Vector Lab.), after which the complex was visualised using
diaminobenzidine and hydrogen peroxide. Slides were
counterstained with haematoxylin, dehydrated and mounted
in Depex. The percentage of neoplasteic cells that show
staining for class I and II MHC and TAP-1 was determined,
with normal epithelium and cells of the immune system
serving as positive internal controls for class I MHC and
TAP-1 and columnar epithelium and infiltrating immune cells
for class II. Primary tumours and lymph node metastases
were classified according to the percentage of neoplastic cells
that were stained. Three expression patterns were discerned
for class I MHC and TAP-1 expression: positive (+), when
virtually all neoplastic cells show membranous staining;
Table I Features of primary antibodies used in this study
Name Type Antigen Source Pretreatment Titre Incubation
Pankeratin Polyclonal rabbit Broad-spectrum Dakopatts, Glostrup, 30 min, 37°C with 1:400 RT, 60 min
cytokeratins Denmark 0.5% trypsina
LN3 MAb mouse HLA-DR Biotech, Breieich, Germany 2 x 5 min, 100C in 1:25 4°C overnight
lead thiocyanateb
HC-A2 MAb mouse HLA-A Stam et al. (1986) 2 x 5 min, 95°C in TUFP 1:500 RT, 60 min
HC1O MAb mouse HLA-B/C Stam et al. (1986) None 1:1,000 RT, 60 min
TAP-1 Polyclonal rabbit Human TAP-I Cromme et al. (1993c) 2 x 5 min, 95'C in TUF 1:400 RT, 60 min
aDigestion with 0.3% (w/v) trypsin in 0.5% calcium chloride (pH 7.8). bSaturated solution of lead thiocyanate. 'TUF, target unmasking fluid
(Kreatech, Amsterdam, The Netherlands) applied according to manufacturer's instructions. RT, room temperature; MAb, monoclonal antibody.
Table II Immunohistochemical staining patterns for class I and II MHC and TAP-I in primary carcinomas and lymph
node metastases (LN)
HLA-A HLA-B/C TAP-I HLA-DR MHC-I
Patient Stage HPV Tumour LN Tumour LN Tumour LN Tumour LN Trend
77-1856 IIA 33 + + + + + + + - =
78-1019 IB 18 + + + + + + + - -
70-2049 IB X + +1- + +/- + + - + - +
72-5453 IIA 16 + +/- + +/- + +/- + - 4'
73-4950 IB ND + +1 + +1- + +1 - - 4
78-3361 IIA 16 + +/- + +/- + +/- - - 4
70-2774 IB ND +/- +_b +/_ +/- +/_ +/- + - -
71-3857 IIA 16 +/- - +/- - +/- - - - 4'
76-3334 IIA 16 +/- - +/- - +/- - + - +
76-3711 IB 16 +/- - +/- - +/- - - - 4'
78-1401 IB 31 +/- - +/- - +/- - - - +
83-3968 IB 16 +/- - +/- - +/- - - - 4'
72-831 IB 16 + _b + _ + _ + 44'
76-1849 IB 18 + - + - + - + - 44
79-766 IB 16 + - + - + - - - 44
80-5041 IB 18 +/- +/- +1- +1- +/- +/- - - =
70-746 IIA 16 - - - - - - - - =
70-2486 IIA 16 - - - - - - - - =
75-184 IIA 16 - - - - - - + - =
77-6541 IIA 16 - - - - - - - - =
aMHC-1 trend: =, similar staining pattern for HLA and TAP-1 in primary tumour and lymph node; 4', more
down-regulation inlymphnodethaninprimary tumour (+/-compared with +, or - compared with +/-); +4, negative
MHC-I expression in lymph node while primary tumour is positive. bWeakly positive cytoplasmic staining. Lesions were
scored as + when virtually all neoplastic cells showed positive membranous staining, - when virtually all neoplastic cells
showed strongly reduced or negative staining as compared with internal control cells and +/-when positively staining
tumour areas were observed adjacent to negative areas. ND, not determinable.1178 F.V. CROMME et al.
negative (-), when virtually all neoplastic cells show strongly
reduced to negative staining; heterogenous (±), when groups
of positively staining neoplastic cells were observed adjacent
to groups of negative cells, the latter generally accounting for
25-75% of the neoplastic cells in a section. For class II
MHC expression, lesions were classified as positive when
areas of neoplastic cells, generally comprising 25% or more
of the neoplastic cells in a section, showed positive staining
for class II MHC. When only a few scattered neoplastic cells
were stained, lesions were not scored as up-regulated.
Statistical analysis of the frequencies of class I and II
MHC changes was performed with a chi-square test, employ-
ing a BMDP statistical software analysis program (Cork,
Ireland). P-values equal to or lower than 0.01 were regarded
to indicate a statistically significant difference.
Results
HPV distribution
By using general primer (GP5/6)-mediated polymerase chain
reaction (PCR) the presence of human papillomavirus (HPV)
DNA was assessed in primary tumours of 18 out of the 20
carcinomas analysed. The remaining two samples were PCR
negative with both the GP primers and with the human
P-globin-specific control primer set, indicating poor target
DNA quality. Subsequently, GP-positive samples were sub-
jected to type-specific PCR, resulting in 12 HPV 16-, three
HPV 18-, one HPV 31- and one HPV 33-positive cases. One
carcinoma did not react with the type-specific primers, and
was therefore typed as HPV-X (Table II).
Presence and typing of HPV in the metastasised neoplastic
cells in the lymph node was also analysed. No differences
were found in HPV types between the primary tumours and
lymph nodes.
Class I MHC and TAP-I expression in primary tumours
After ascertaining general epitope conservation and the
epithelial nature of the neoplastic cells with a keratin-specific
antibody, immunohistochemical staining for class I MHC
expression was analysed with antibodies specific for HLA-A
(i.e. HC-A2) and HLA-B/C (i.e. HCIO) locus products.
All carcinomas showed similar staining patterns for HLA-
A and HLA-B/C expression at the primary tumour site
(Table II). An example is given in Figure 1, in which areas of
neoplastic cells of carcinoma 70-746 show lack of staining for
both HLA-A (Figure la) and HLA-B/C (Figure lb), whereas
immune cells in the stroma and within the neoplastic area are
labelled for both antigens.
From the 20 primary tumours analysed, four were scored
as negative for HLA-A and HLA-B/C, i.e. virtually all neo-
plastic cells show loss of staining. An additional seven were
judged as heterogeneous, i.e. positive tumour areas adjacent
to negative ones. The remaining nine carcinomas were scored
as positive, i.e. the vast majority of neoplastic cells showing
membranous staining.
Expression of one of the subunits of the transporter
associated with antigen presentation (TAP-1) was analysed
with a polyclonal serum, specific for the TAP-1 protein
(Cromme et al., 1993c). As shown in Figure lc, loss of
staining for TAP-1 was found in those neoplastic areas of
primary tumours that lacked staining for HLA-A and HLA-
B/C locus products. This congruency was invariably found in
all primary tumours (Table II), which is in accordance with
previous findings (Cromme et al., 1993c).
Class I MHC and TAP-i expression in lymph node metastases
In the lymph nodes the same congruency between class I
MHC and TAP-1 expression was found (Table II). Meta-
stasised neoplastic cells of carcinoma 76-1849 show loss of
HLA-B/C expression (Figure 2b) and staining for TAP-1
(Figure 2c). The same area is negative for HLA-A expression
as well (not shown).
However, the frequency of class I MHC and TAP-1 down-
regulation was higher in the metastasised neoplastic cells in
the lymph nodes than in their primary tumours. An increase
in down-regulation of class I MHC expression was found in
12 patients when comparing primary tumours and meta-
stases, as indicated in the MHC-I trend column of Table II.
An example is given in Figure 2, in which carcinomas 76-
1849 shows positive membranous staining for HLA-B/C at
the primary tumour site (Figure 2a), while metastasised cells
are clearly negative for HLA-B/C (Figure 2b). In the remain-
ing eight patients the expression patterns in primary tumours
and metastases were similar. Two lesions exhibited weak
cytoplasmic staining for HLA-A locus products in some
(Table II: carcinoma 70-2774) or all (carcinoma 72-831)
neoplastic cells. However, since no membranous staining was
observed, these were scored as heterogeneous and negative,
respectively, for HLA-A cell-surface expression.
For statistical analysis of the difference in MHC and TAP-
1 expression between primary tumours and lymph node
metastases, heterogeneous and negative expression patterns
a
b
c
Figure 1 Immunohistochemical staining for class I MHC and
TAP-1 expression of primary cervical carcinoma 70-746. a, Stain-
ing for HLA-A locus products shows positivity in stroma cells
and infiltrating immune cells, while neoplastic cells are negative.
b, Consecutive tissue section of the same primary tumour reveals
loss of HLA-B/C locus expression in the same neoplastic area
that is negative for HLA-A. Internal staining control cells, i.e.
immune cells, are positive. c, Identical tumour area is negative for
TAP-I protein. Size bars represent 25jim.LOSS OF MHC-I AND TAP-1 EXPRESSION AND HLA-DR UP-REGULATION IN CERVICAL CANCER METASTASES 1179
a
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Figure 2 Staining for HLA-B/C and TAP-1 in the primary
tumour (a) and lymph node metastasis (b and c) of carcinoma
76-1849. a, The primary tumour shows positive membranous
staining for HLA-B/C locus expression on neoplastic cells. b,
Metastasised cells in the lymph node from the same patient show
a clear lack of HLA-B/C expression, while lymph cells are
positive. c, The identical neoplastic area is also negative for
TAP-1
were taken together and scored as down-regulated. Such
down-regulation was observed in 18 out of 20 metastases,
compared with 11 out of 20 primary tumours. This difference
is statistically significant by chi-square test (P-value 0.01).
Class II MHC expression in primary tumours
Class II MHC expression was analysed by immunohisto-
chemistry with an antibody recognising HLA-DR locus pro-
ducts (i.e. LN3). Activated T cells, B cells and macrophages
served as internal positive controls, whereas normal
squamous epithelium present in the same section was never
stained. When a substantial number of neoplastic areas, i.e.
25% or more of the neoplastic cells in a section, stain for
HLA-DR, lesions were classified as positive (+). As shown
for carcinoma 72-5453 in Figure 3a, neoplastic cells clearly
stain positive for HLA-DR at the cell membrane, in addition
to positive staining of immune cells in the stroma. In total,
nine out of 20 primary tumours were scored as positive for
HLA-DR (Table II).
Figure 3 Class II MHC expression in primary tumour (a) and
metastasised cells in the lymph node (b) of cervical carcinoma
72-5453, as determined with an HLA-DR-specific antibody. a,
Neoplastic cells at the primary tumour site show up-regulated
HLA-DR expression, with staining localised at the cell mem-
brane. Immune cells in the stroma are positive as well. b, Meta-
stasised neoplastic cells of the same patient exhibit no HLA-DR
expression, while lymph cells are clearly positive.
Class II MHC expression in lymph node metastases
No HLA-DR expression was observed on neoplastic
epithelial cells in the lymph nodes, while lymphocytes in the
nodes stained positive. Corresponding tumours at the
primary site were scored as positive in nine cases, and an
example of this differential staining is shown in Figure 3.
Lack of staining for HLA-DR of metastasised neoplastic
cells was observed (Figure 3b), while the same patient
exhibits up-regulated HLA-DR expression in the primary
tumour (Figure 3a). The difference in frequency of HLA-DR
expression between primary tumours and metastases is statis-
tically highly significant (P-value 0.002).
Discussion
Certain human papillomavirus (HPV) types are considered to
play an important role in cervical carcinogenesis (Zur
Hausen, 1989). The major transformation protein E7 from
high-risk HPV types (i.e. HPV 16 and 18) interferes with cell
cycle control by complexing with the retinoblastoma tumour-
suppressor protein (PRb) (Munger et al., 1989), and the E7
open reading frame is consistently transcribed in HPV-
containing neoplastic cervical cells (Broker et al., 1989; van
den Brule et al., 1991). This viral protein has been shown to
be immunogenic in vitro (Chen et al., 1991), and immunisa-
tion with HPV 16-E7-derived peptide resulted in a protective
CTL response in mice (Feltkamp et al., 1993). Therefore the
loss of class I MHC surface expression observed in HPV-
positive neoplastic cervical cells (Connor & Stern, 1990;
Cromme et al., 1993a) could be of importance to escape the
cellular adaptive immune response.1180 F.V. CROMME et al.
This study shows that metastasised cervical carcinoma cells
displayed a statistically significant increase in frequency of
class I MHC down-regulation (P = 0.01) as compared with
the primary tumour. This observation lends support to the
hypothesis that class I MHC-negative tumour cells possess a
selective advantage to metastasise and further underlines an
important role of the cellular immune response in preventing
widespread disease. The latter is also indicated by a 10 times
higher risk of developing premalignant cervical lesions (CIN)
in women receiving immunosuppressive agents (Sillman &
Sedlis, 1987) and the significantly shorter disease-free survival
of HIV-seropositive cervical cancer patients (Maiman et al.,
1993).
The dominant role for the adaptive immune response in
controlling metastasis is further supported by the frequent
loss of class I MHC expression in vivo during lymph node
metastasis in breast, colon, urinary and kidney carcinomas
(Cordon-Cardo et al., 1991) and in melanomas (Lopez-Nevot
et al., 1986; Ruiter et al., 1986). On the other hand, several
reports have shown that an increase in expression of class I
MHC results in a higher number of metastases in mice (De
Baetselier et al., 1980; Katzav et al., 1984; Algarra et al.,
1991). This could be due to a decreased natural killer (NK)-
cell susceptibility of class I MHC-positive cells, according to
the hypothesis that NK cells recognise 'missing self (Karre et
al., 1986). However, restoration of class I MHC expression
by y-interferon treatment of melanoma cells reduces their
metastatic potential (Zoller et al., 1988), indicating that the
increased efficacy of T-cell response can overcome the loss of
a non-adaptive immune defence in vitro.
Recently we have shown that the down-regulation of class
I MHC expression is strongly associated with loss of the
transporter associated with antigen presentation (TAP) in
primary cervical carcinomas (Cromme et al., 1993c). This fits
into the model of post-transcriptional regulation of class I
MHC expression (Cromme et al., 1993b), in which lack of
class I MHC stabilisation in the ER occurs when peptide
levels are reduced owing to loss of TAP. The observation in
this study that the increased frequency of class I MHC
down-regulation in lymph node metastases is consistently
accompanied by loss of TAP-1 protein confirms and extends
the relationship between the expression of HLA and TAP-1
and indicates a role during tumorigenesis in vivo. The regula-
tion of TAP-1 documented in this and other studies
(Cromme et al., 1993c; Restifo et al., 1993) may not therefore
be epiphenomenon but a target for selection during progres-
sion of malignant disease. Further investigation into the
mechanisms of TAP-1 down-regulation could provide the
tool to restore antigen presentation and consequently render
neoplastic cells sensitive to CD8+ CTL-mediated immune
therapy.
Two patients in this study showed no down-regulation of
class I MHC expression in either the primary tumour site or
the lymph node, but were HLA-DR positive in the primary
tumour. Presumably other mechanisms of immune escape
can operate in these cases. Under some circumstances up-
regulated class II MHC expression on keratinocytes can
result in T-cell anergy or tolerance, presumably due to an
incorrect antigen presentation (Gaspari et al., 1988; Bal et al.,
1990). Therefore de novo HLA-DR expression on neoplastic
epithelial cells as observed in this and other studies (Glew et
al., 1992; Cromme et al., 1993a) may have induced a state of
T-cell anergy.
Alternatively, class II MHC molecules may serve as restric-
tion elements for tumour-specific CD4+ CTLs. In line with
this is the finding that peripheral CD4+ T cells in HPV-
seropositive donors can lyse autologous B cells after pulsing
with HPV 16-E7-encoded peptides, presumably in a class II
MHC-restricted fashion (Altmann et al., 1992). Provided that
endogenous HPV proteins can enter the class II secretory
pathway in vivo, in analogy with cytosolic vaccinia proteins
(Jaraquemada et al., 1990), the up-regulated HLA-DR ex-
pression could result in specific lysis of cervical tumour cells
by CD4+ T cells. This would explain selection for HLA-DR-
negative tumour cells during metastasis.
However, it cannot be excluded that the difference in
frequency of HLA-DR expression between primary tumours
and lymph node metastases is related to differences in local
cytokine production (i.e. y-interferon, tumour necrosis factor)
and therefore needs to be considered as a bystander effect.
Further research into the nature of infiltrating immune
cells and their state of activation is required to establish
which immune cell population has been primed. This could
further elucidate which target cell recognition structures are
negatively selected for during cervical carcinogenesis.
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